Holen Sie sich die Stockscreener-App
8.03
5.38%
0.41
Handel nachbörslich:
8.25
0.22
+2.74%
Schlusskurs vom Vortag:
$7.62
Offen:
$7.59
24-Stunden-Volumen:
1.01M
Relative Volume:
0.79
Marktkapitalisierung:
$191.24M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-29.25M
KGV:
-6.7707
EPS:
-1.186
Netto-Cashflow:
$-22.80M
1W Leistung:
-18.31%
1M Leistung:
+126.20%
6M Leistung:
+78.44%
1J Leistung:
+154.11%
1-Tages-Spanne:
$7.51
$8.61
1-Wochen-Bereich:
$7.51
$9.99
52-Wochen-Spanne:
$1.73
$10.43
Sagimet Biosciences Inc Stock (SGMT) Company Profile
Firmenname
Sagimet Biosciences Inc
Sektor
Branche
Telefon
(650) 561-8600
Adresse
155 BOVET RD., SUITE 303, SAN MATEO
Vergleichen Sie SGMT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SGMT
Sagimet Biosciences Inc
|
8.03 | 191.24M | 0 | -29.25M | -22.80M | -1.186 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Sagimet Biosciences Inc Stock (SGMT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-06 | Eingeleitet | Oppenheimer | Outperform |
| 2024-11-12 | Eingeleitet | UBS | Buy |
| 2024-06-28 | Herabstufung | Goldman | Buy → Neutral |
| 2024-05-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-03-25 | Eingeleitet | Leerink Partners | Outperform |
| 2023-08-08 | Eingeleitet | Goldman | Buy |
| 2023-08-08 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-08-08 | Eingeleitet | Piper Sandler | Overweight |
| 2023-08-08 | Eingeleitet | TD Cowen | Outperform |
Alle ansehen
Sagimet Biosciences Inc Aktie (SGMT) Neueste Nachrichten
Wall Street Analysts Predict a 437.05% Upside in Sagimet Biosciences Inc. (SGMT): Here's What You Should Know - MSN
Sagimet Biosciences’ SWOT analysis: promising FASN inhibitor stock faces funding hurdles By Investing.com - Investing.com South Africa
Sagimet Biosciences’ SWOT analysis: promising FASN inhibitor stock faces funding hurdles - Investing.com
Sagimet stock holds steady as JMP reiterates $31 price target By Investing.com - Investing.com Nigeria
Sagimet Biosciences Inc: Analyzing SGMT Stock Trends - investchronicle.com
Two Sigma Investments LP Trims Holdings in Sagimet Biosciences Inc. (NASDAQ:SGMT) - Defense World
What Makes Sagimet Biosciences Inc. (SGMT) a Strong Momentum Stock: Buy Now? - Yahoo Finance
Sagimet Biosciences updates executive compensation By Investing.com - Investing.com South Africa
Sagimet Biosciences updates executive compensation - Investing.com
Sagimet Biosciences Elects New Directors at Annual Meeting - TipRanks
Sagimet Biosciences to Host Virtual KOL Event, “A New - GlobeNewswire
Sagimet Biosciences to host KOL event on denifanstat results - TipRanks
Sagimet Biosciences (SGMT) to Highlight Positive Phase 3 Acne Treatment Results | SGMT Stock News - GuruFocus
Sagimet Biosciences to Host Virtual KOL Event, 'A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne” on June 16, 2025 - The Manila Times
Sagimet Biosciences to Host Virtual KOL Event, “A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne” on June 16, 2025 - GlobeNewswire
Breakthrough Phase 3 Results: Novel Oral Acne Drug Shows Promise for 50M US Patients - Stock Titan
Analysts Set Sagimet Biosciences Inc. (NASDAQ:SGMT) PT at $23.17 - Defense World
Squarepoint Ops LLC Grows Stake in Sagimet Biosciences Inc. (NASDAQ:SGMT) - Defense World
Sagimet Biosciences (NASDAQ:SGMT) Stock Price Expected to Rise, Jones Trading Analyst Says - Defense World
Sagimet Biosciences (SGMT) Price Target Raised by Jones Trading - GuruFocus
Sagimet Biosciences (SGMT) Price Target Raised by Jones Trading | SGMT Stock News - GuruFocus
Sagimet Biosciences Shares Surge After Promising Phase 3 Acne Drug Results - MSN
Sagimet Biosciences price target raised to $27 from $15 at JonesResearch - TipRanks
Sagimet Biosciences (SGMT) Target Price Raised to $27 by Analyst | SGMT Stock News - GuruFocus
Uncovering Hidden Gems: Penny Stocks To Consider In June 2025 - Yahoo Finance
Jane Street Group LLC Purchases New Stake in Sagimet Biosciences Inc. (NASDAQ:SGMT) - Defense World
Promising Potential of Sagimet Biosciences: Buy Rating Affirmed by Positive Phase 3 Trial Results and Strategic Advancements - TipRanks
Sagimet: Positive China Partner Acne Vulgaris Data Bodes Well For TVB-3567 (SGMT) - Seeking Alpha
leerink partners maintains outperform rating on sagimet stock By Investing.com - Investing.com Canada
Sagimet Biosciences (SGMT) Surges on Successful Acne Drug Trial in China - GuruFocus
Sagimet partner Ascletis announces significant Phase III acne data - The Pharma Letter
Sector Update: Health Care - MarketScreener
Sagimet's Partner Achieves Positive Results With Oral Acne Drug In Phase 3 Acne Trial In China, Stock Jumps - Benzinga
leerink partners maintains outperform rating on sagimet stock - Investing.com
Sagimet Biosciences shares soar on positive acne treatment trial results By Investing.com - Investing.com South Africa
Sagimet Biosciences shares soar on positive acne treatment trial results - Investing.com
Sagimet stock climbs on acne trial data (SGMT:NASDAQ) - Seeking Alpha
Sagimet Biosciences Announces Phase 3 Trial Success - TipRanks
Sagimet Biosciences Announces Positive Phase 3 Results for - GlobeNewswire
Sagimet Biosciences Says Acne Vulgaris Treatment Meets Phase 3 Trial Primary, Secondary Endpoints - marketscreener.com
Sagimet Biosciences Announces Positive Phase 3 Results For Denifanstat - marketscreener.com
Sagimet Biosciences Reports Successful Phase 3 Results for Denifanstat in Moderate to Severe Acne and Initiates Phase 1 Trial for TVB-3567 - Nasdaq
Breakthrough Acne Treatment Achieves Phase 3 Success: First New Oral Drug Mechanism in 40 Years Shows Promise - Stock Titan
Sagimet Biosciences’ SWOT analysis: denifanstat’s potential in MASH treatment - Investing.com Australia
Sagimet Biosciences’ SWOT analysis: denifanstat’s potential in MASH treatment By Investing.com - Investing.com Nigeria
Sagimet Biosciences to host KOL event on denifanstat, resmetirom - TipRanks
Sagimet Biosciences (SGMT) to Host Key Opinion Leader Event on I - GuruFocus
Sagimet Biosciences to Host Virtual KOL Event, “Evaluating - GlobeNewswire
Finanzdaten der Sagimet Biosciences Inc-Aktie (SGMT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Sagimet Biosciences Inc-Aktie (SGMT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Martins Eduardo Bruno | Chief Medical Officer |
Jul 19 '24 |
Sale |
3.10 |
8,357 |
25,910 |
81,213 |
| Rozek Elizabeth | General Counsel and CCO |
Jul 19 '24 |
Sale |
3.10 |
10,914 |
33,830 |
160,506 |
| Kemble George | Executive Chairman |
Jul 19 '24 |
Sale |
3.10 |
14,062 |
43,605 |
142,318 |
0.39%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):